Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13439MR)

This product GTTS-WQ13439MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13439MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11556MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MG-A271
GTTS-WQ5414MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ8389MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ8812MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ12105MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ9824MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ9892MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ9174MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN-529
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW